Cargando…

Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders

The global rise in opioid-related harms has impacted the United States severely. Current efforts to manage the opioid crisis have prompted a re-evaluation of many of the existing roles in the healthcare system, in order to maximize their individual effects on reducing opioid-associated morbidity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bach, Paxton, Hartung, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717996/
https://www.ncbi.nlm.nih.gov/pubmed/31474225
http://dx.doi.org/10.1186/s13722-019-0158-0
_version_ 1783447659412979712
author Bach, Paxton
Hartung, Daniel
author_facet Bach, Paxton
Hartung, Daniel
author_sort Bach, Paxton
collection PubMed
description The global rise in opioid-related harms has impacted the United States severely. Current efforts to manage the opioid crisis have prompted a re-evaluation of many of the existing roles in the healthcare system, in order to maximize their individual effects on reducing opioid-associated morbidity and preventing overdose deaths. As one of the most accessible healthcare professionals in the US, pharmacists are well-positioned to participate in such activities. Historically, US pharmacists have had a limited role in the surveillance and treatment of substance use disorders. This narrative review explores the literature describing novel programs designed to capitalize on the role of the community pharmacist in helping to reduce opioid-related harms, as well as evaluations of existing practices already in place in the US and elsewhere around the world. Specific approaches examined include strategies to facilitate pharmacist monitoring for problematic opioid use, to increase pharmacy-based harm reduction efforts (including naloxone distribution and needle exchange programs), and to involve community pharmacists in the dispensation of opioid agonist therapy (OAT). Each of these activities present a potential means to further engage pharmacists in the identification and treatment of opioid use disorders (OUDs). Through a careful examination of these approaches, we hope that new strategies can be adopted to leverage the unique role of the community pharmacist to help reduce opioid-related harms in the US.
format Online
Article
Text
id pubmed-6717996
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67179962019-09-06 Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders Bach, Paxton Hartung, Daniel Addict Sci Clin Pract Review The global rise in opioid-related harms has impacted the United States severely. Current efforts to manage the opioid crisis have prompted a re-evaluation of many of the existing roles in the healthcare system, in order to maximize their individual effects on reducing opioid-associated morbidity and preventing overdose deaths. As one of the most accessible healthcare professionals in the US, pharmacists are well-positioned to participate in such activities. Historically, US pharmacists have had a limited role in the surveillance and treatment of substance use disorders. This narrative review explores the literature describing novel programs designed to capitalize on the role of the community pharmacist in helping to reduce opioid-related harms, as well as evaluations of existing practices already in place in the US and elsewhere around the world. Specific approaches examined include strategies to facilitate pharmacist monitoring for problematic opioid use, to increase pharmacy-based harm reduction efforts (including naloxone distribution and needle exchange programs), and to involve community pharmacists in the dispensation of opioid agonist therapy (OAT). Each of these activities present a potential means to further engage pharmacists in the identification and treatment of opioid use disorders (OUDs). Through a careful examination of these approaches, we hope that new strategies can be adopted to leverage the unique role of the community pharmacist to help reduce opioid-related harms in the US. BioMed Central 2019-09-02 2019 /pmc/articles/PMC6717996/ /pubmed/31474225 http://dx.doi.org/10.1186/s13722-019-0158-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Bach, Paxton
Hartung, Daniel
Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title_full Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title_fullStr Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title_full_unstemmed Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title_short Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title_sort leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717996/
https://www.ncbi.nlm.nih.gov/pubmed/31474225
http://dx.doi.org/10.1186/s13722-019-0158-0
work_keys_str_mv AT bachpaxton leveragingtheroleofcommunitypharmacistsinthepreventionsurveillanceandtreatmentofopioidusedisorders
AT hartungdaniel leveragingtheroleofcommunitypharmacistsinthepreventionsurveillanceandtreatmentofopioidusedisorders